Proteomics

Dataset Information

0

Bruton’s Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer

ABSTRACT: The covalent Bruton’s Tyrosine Kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it also has off-target effects and multiple mechanisms of resistance, including the C481S mutation. We hypothesized that small molecule-induced BTK degradation might be able to overcome some of the limitations of traditional enzymatic inhibitors. Here, we demonstrate that BTK degradation results in more durable suppression of signaling and proliferation in cancer cells than BTK inhibition and that BTK degraders are able to efficiently degrade BTK C481S. Moreover, we generated DD-03-171, an optimized lead compound that exhibits enhanced anti-proliferative effects on mantle cell lymphoma (MCL) cells in vitro as well as efficacy in a patient-derived xenograft model of MCL. These data suggest that targeted BTK degradation is an effective therapeutic approach in treating MCL and overcoming ibrutinib resistance, thereby addressing a major unmet need in the treatment of MCL and other B-cell lymphomas.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Eric Fischer  

LAB HEAD: Eric S. Fischer

PROVIDER: PXD010568 | Pride | 2019-01-25

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
esf_1051.raw Raw
esf_1052.raw Raw
esf_1053.raw Raw
esf_1054.raw Raw
esf_1055.raw Raw
Items per page:
1 - 5 of 25
altmetric image

Publications

The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy. We hypothesized that small-molecule-induced BTK degradation may overcome some of the limitations of traditional enzymatic inhibitors. Here, we demonstrate that BTK degradation results in potent suppression of signaling and proliferation i  ...[more]

Similar Datasets

Transcriptomics Synergistic activity of BET protein antagonist-based combinations in Mantle Cell Lymphoma cells sensitive or resistant to ibrutinib
2015-12-31 | E-GEOD-70651 | biostudies-arrayexpress
Transcriptomics Transcriptional responses of mantle cell lymphoma (MCL) lines to IKKB inhibition
2013-12-01 | E-GEOD-52434 | biostudies-arrayexpress
Transcriptomics Synergistic activity of BET protein antagonist-based combinations in Mantle Cell Lymphoma cells sensitive or resistant to ibrutinib
2015-12-31 | GSE70651 | GEO
Transcriptomics Transcriptional responses of mantle cell lymphoma (MCL) lines to IKKB inhibition
2013-12-01 | GSE52434 | GEO
Transcriptomics Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma
2024-02-19 | GSE227976 | GEO
Transcriptomics XPO1 inhibition antagonizes MCL via nuclear retention of IkB: Selinexor demonstrates antitumor activities in both ibr-sensitive and ibr-resistant tumor cells
2018-07-10 | GSE116810 | GEO
Proteomics ABPP of Ibrutinib Resistance in B Cell Malignancies
2018-10-26 | PXD005734 | Pride
Transcriptomics BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against Mantle Cell Lymphoma cells
2019-04-26 | GSE98268 | GEO
Genomics Ibrutinib induces a global chromatin reorganisation in chronic lymphocytic leukaemia
2019-06-01 | E-MTAB-6410 | biostudies-arrayexpress
Transcriptomics Chromatin structure analysis for two patients on Ibrutinib and showing disease progression in chronic lymphocytic leukaemia
2020-09-01 | E-MTAB-8220 | biostudies-arrayexpress